Table of Content


Introduction
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adastra Pharmaceuticals Inc, 2021
Pipeline by Apollo Therapeutics LLC, 2021
Pipeline by Arc Therapeutics Inc, 2021
Pipeline by Astex Pharmaceuticals Inc, 2021
Pipeline by Aucentra Therapeutics Pty Ltd, 2021
Pipeline by Blueprint Medicines Corp, 2021
Pipeline by Cyclacel Pharmaceuticals Inc, 2021
Pipeline by Monte Rosa Therapeutics Inc, 2021
Pipeline by Neosome Life Sciences LLC, 2021
Pipeline by Nuvation Bio Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Prous Institute for Biomedical Research SA, 2021
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Pipeline by Tiziana Life Sciences Plc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021